NASDAQ:HURA TuHURA Biosciences (HURA) Stock Price, News & Analysis $3.18 -0.03 (-0.93%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$3.20 +0.01 (+0.47%) As of 05/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About TuHURA Biosciences Stock (NASDAQ:HURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TuHURA Biosciences alerts:Sign Up Key Stats Today's Range$3.11▼$3.2950-Day Range$2.83▼$4.2352-Week Range$1.80▼$7.93Volume50,315 shsAverage Volume241,110 shsMarket Capitalization$138.90 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company OverviewTuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Read More… Receive HURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TuHURA Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HURA Stock News HeadlinesTuHURA Biosciences: Encountering Serious Cash Issues And A Long TimelineMay 28 at 4:08 PM | seekingalpha.comZacks Small Cap Issues Pessimistic Outlook for HURA EarningsMay 24, 2025 | americanbankingnews.com“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 30, 2025 | Brownstone Research (Ad)Kineta and TuHURA Biosciences Announce Merger AgreementMay 23, 2025 | tipranks.comResearch Analysts Offer Predictions for HURA FY2027 EarningsMay 23, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for HURA FY2025 Earnings?May 20, 2025 | americanbankingnews.comHURA: First Quarter 2025 ResultsMay 19, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 15, 2025 | prnewswire.comSee More Headlines HURA Stock Analysis - Frequently Asked Questions How have HURA shares performed this year? TuHURA Biosciences' stock was trading at $4.09 at the beginning of 2025. Since then, HURA stock has decreased by 22.2% and is now trading at $3.18. View the best growth stocks for 2025 here. How were TuHURA Biosciences' earnings last quarter? TuHURA Biosciences (NASDAQ:HURA) released its earnings results on Thursday, May, 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. Who are TuHURA Biosciences' major shareholders? Top institutional investors of TuHURA Biosciences include Apollon Wealth Management LLC (0.26%), Suncoast Equity Management (0.23%), Sabal Trust CO (0.09%) and Hurlow Wealth Management Group Inc. (0.07%). How do I buy shares of TuHURA Biosciences? Shares of HURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2025Today5/30/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HURA Previous SymbolNASDAQ:HURA CIK1498382 WebN/A Phone(813) 875-6600Fax604-608-5685EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside+298.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.32 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-152.88% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.11) per share Price / Book-0.77Miscellaneous Outstanding Shares43,680,000Free Float42,200,000Market Cap$138.90 million OptionableN/A Beta0.53 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:HURA) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.